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A B S T R A C T
Background: We evaluated existing data on the prophylactic eﬃcacy of atovaquone-proguanil (AP) in order to
determine whether prophylaxis in travellers can be discontinued on the day of return from a malaria-endemic
area instead of seven days after return as per currently recommended post-travel schedule.
Methods: PubMed and Embase databases were searched to identify relevant studies. This PROSPERO-registered
systematic review followed PRISMA guidelines. The search strategy included terms or synonyms relevant to AP
combined with terms to identify articles relating to prophylactic use of AP and inhibitory and half-life properties
of AP. Studies considered for inclusion were: randomized controlled trials, cohort studies, quasi-experimental
studies, open-label trials, patient-control studies, cross-sectional studies; as well as case-series and non-clinical
studies. Data on study design, characteristics of participants, interventions, and outcomes were extracted.
Primary outcomes considered relevant were prophylactic eﬃcacy and prolonged inhibitory activity and half-life
properties of AP.
Results: The initial search identiﬁed 1,482 publications, of which 40 were selected based on screening.
Following full text review, 32 studies were included and categorized into two groups, namely studies in support
of the current post-travel regimen (with a total of 2,866 subjects) and studies in support of an alternative
regimen (with a total of 533 subjects).
Conclusion: There is limited direct and indirect evidence to suggest that an abbreviated post-travel regimen for
AP may be eﬀective. Proguanil, however, has a short half-life and is essential for the synergistic eﬀect of the
combination. Stopping AP early may result in mono-prophylaxis with atovaquone and possibly select for ato-
vaquone-resistant parasites. Furthermore, the quality of the studies in support of the current post-travel regimen
outweighs the quality of the studies in support of an alternative short, post-travel regimen, and the total sample
size of the studies to support stopping AP early comprises a small percentage of the total sample size of the
studies performed to establish the eﬃcacy of the current AP regimen. Additional research is required — espe-
cially from studies evaluating impact on malaria parasitaemia and clinical illness and conducted among tra-
vellers in high malaria risk settings — before an abbreviated regimen can be recommended in current practice.
PROSPERO registration number: CRD42017055244.
1. Introduction
Atovaquone-proguanil (AP; marketed as Malarone® or Malanil® or as
generic brands such as Atovaquone Plus®) is a convenient choice for
malaria drug prophylaxis in short-term travel [1,2]. ‘Short-term’ is
considered to be a travel of three weeks or less [3]. The current ap-
proved regimen of AP for malaria chemoprophylaxis is daily adminis-
tration of one tablet of 250 mg atovaquone/100 mg proguanil hydro-
chloride beginning one to two days before entry into a malaria-endemic
area, continued during exposure, and discontinued seven days after
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leaving the endemic area [1]. This drug is highly eﬀective in preventing
clinical malaria episodes, but non-compliance and non-adherence, in a
proportion of patients due to (mainly gastrointestinal) adverse events,
are major contributors to a reduced eﬀectiveness.
AP is approved for causal prophylaxis against P. falciparum and does
not prevent the formation of dormant liver stages (hypnozoites) by P.
vivax and P. ovale, as illustrated by several case-reports [4–7]. Pre-
sumptive primaquine treatment may be required to eliminate the
hypnozoites in order to prevent relapses due to these malaria species.
Atovaquone belongs to the hydroxynapthoquinone class of com-
pounds and inhibits the parasite mitochondrial electron transport and
ATP synthesis, whereas the active proguanil metabolite, cycloguanil,
inhibits plasmodial dihydrofolate reductase. Proguanil works sy-
nergistically with atovaquone, as it lowers the eﬀective concentration
of atovaquone needed to collapse mitochondrial potential [8,9]. Both
drugs are active against erythrocytic and pre-erythrocytic stages of
Plasmodium species, and thus AP exhibits causal prophylactic activity
against liver stages and activity against plasmodial blood stages
[10,11]. Because of this causal prophylactic activity, AP can be dis-
continued seven days after return from a malaria-endemic area instead
of one month in the case of antimalarials with only suppressive pro-
phylaxis against blood stages of malaria.
The elimination half-life of proguanil is only 12–21 h in both adults
and children, while the half-life of atovaquone is two to three days in
adults and one to two days in children [8]. However, Edstein and col-
leagues determined the half-life of atovaquone to be 5.9 days in a study
with three volunteers [12], thus giving rise to concerns of a drug
partners mismatch time window, which has only very rarely been re-
ported to impact the clinical course of patients [13].
Nixon et al. reviewed pharmacokinetic and –dynamic properties of
this slow-acting drug (atovaquone) [14]. Molecular surveillance data
from Gabon and Ethiopia [15] demonstrated that in the absence of drug
pressure, the occurrence of potentially drug resistance-conveying
polymorphisms remain an exception. Over 500 samples from treatment
failures and other imported isolates to Europe were screened for single-
point, potentially resistance-conferring polymorphisms in the cyto-
chrome b gene. This showed that the prevalence of those mutations in
the European gene pool is well below 1% [16].
AP is well tolerated by the majority of users; however, adverse re-
actions when used as prophylactic agent against malaria are nausea,
vomiting, abdominal pain, headache, and diarrhea [8]. When compared
to other antimalarials currently used for malaria prophylaxis, AP has
been found to have fewer reported adverse events in randomized trials
[17,18].
A recently performed study by Leshem and colleagues did not detect
failures among 421 travellers who discontinued prophylaxis one day
after return from a malaria-endemic area, mostly in Eastern Africa;
however, several methodological shortcomings were acknowledged
[19,20]. These included the choice of a region with limited risk of ex-
posure to malaria, insuﬃcient level of evidence that the drugs were
taken appropriately, and possible recall bias. However, the absence of
comprehensive funding opportunities needed to conduct a study of
considerable complexity and study subject numbers makes it challen-
ging to provide a comprehensive, deﬁnitive recommendation. Very few
clinical and pharmacological studies have been performed that have
focused on providing evidence for an abridged AP malaria chemopro-
phylaxis regimen [19].
The objective of this systematic review is to determine the pro-
phylactic eﬃcacy when discontinuing AP in travellers one day after
return from a malaria-endemic area instead of after seven days. In order
to assess whether the currently available evidence supports shortening
post-travel duration of AP, we reviewed and weighed current clinical
and pharmacological data with regard to the prophylactic activity and
prolonged inhibitory activity or half-life properties of AP. Finally, we
suggest a methodologically feasible study approach in order to answer
future questions with regard to malaria prophylaxis.
2. Methods
In this systematic review, we evaluate existing data with regard to
the prophylactic eﬃcacy of AP, in order to determine whether pro-
phylaxis in travellers can be discontinued on the day of return from a
malaria-endemic area instead of seven days later. However, because of
the limited research performed on this topic, we also included studies
with alternative regimens of AP chemoprophylaxis, whilst in an en-
demic area, in support of the prolonged antimalarial activity of AP.
2.1. Search strategy and study selection
The electronic PubMed and Embase databases were consulted to
identify relevant studies. Because AP was registered in 1998, we in-
cluded studies published between 1995 and the present. Relevant stu-
dies identiﬁed by additional reading/citation were also considered for
inclusion. The PROSPERO protocol was registered at http://www.crd.
york.ac.uk (CRD42017055244). The PRISMA guidelines for systematic
reviews were followed in most aspects [21]. The few deviations from
PRISMA guidelines are discussed below.
The search strategy included terms or synonyms relevant to AP
combined with terms to identify articles related to prophylactic use of
AP, or pharmacokinetic properties of AP. The full search strategy is
provided in Appendix 1 and Appendix 2. This search strategy was
veriﬁed by a clinical librarian. Screening on title/abstract and full text
was performed independently by two reviewers. Discrepancies were
resolved by discussion. A recent update of the PubMed and Embase
search was performed in the beginning of September 2017. No language
restrictions were applied, though no studies meeting the inclusion cri-
teria but not written in English were identiﬁed.
2.2. Eligibility: inclusion and exclusion criteria
The PICO format was used to determine the inclusion criteria: (P)
Participants: travellers to malaria-endemic areas, in which travellers
were deﬁned as children and adults (both pregnant and non-pregnant);
(I) Intervention: discontinuation of daily administered AP prophylaxis
one day upon return from a malaria-endemic area; (C) Comparison:
discontinuation of daily administered AP prophylaxis seven days after
return from a malaria-endemic area; (O) Outcome: parasitaemia.
Studies with focus on alternative regimens of AP, deﬁned as dis-
continuation one to seven days after return from a malaria-endemic
area, or an outcome other than parasitaemia such as adverse events,
were also considered for inclusion. The outcomes considered for non-
clinical (e.g. pharmacological or experimental) studies were the half-
life properties of AP or an outcome related to elimination half-life (i.e.
an outcome suggesting the prolonged inhibitory activity of AP).
Criteria for exclusion were: a focus on malaria treatment (except
when there was an emphasis on the duration of the prolonged in-
hibitory activity or half-life properties of AP), a focus on adherence to
prophylaxis, a focus on adverse eﬀects, a focus on resistance (patterns),
a focus on prescribing patterns, or when no abstract or PDF ﬁle was
available.
The following study designs were considered for inclusion: rando-
mized controlled trials, prospective cohort studies, retrospective cohort
studies, quasi-experimental studies, open-label trials, patient-control
studies, cross-sectional studies; case-series, and non-clinical studies.
Pharmacological and experimental studies were considered as non-
clinical, and only papers with a focus on the prolonged inhibitory ac-
tivity or half-life properties of AP were considered and included as non-
clinical studies.
2.3. Data extraction
The following data were extracted: ﬁrst author, publication date,
study design, total number of participants (together with the inclusion
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and exclusion criteria), characteristics of participants (age, sex,
country), intervention and comparison, (primary) outcomes and results.
Primary outcomes considered relevant were prophylactic eﬃcacy (e.g.
parasitaemia) or half-life properties in the case of non-clinical (e.g.
pharmacological or experimental) studies. Data extraction was re-
viewed independently by a second reviewer, and any discrepancies
were resolved by discussion.
2.4. Quality assessment
The methodological quality of the eligible randomized studies was
rated by using the Jadad criteria [22]. The methodological quality of
the eligible non-randomized studies was rated by using the Joanna
Briggs Institute Critical Appraisal tools [23]. The Joanna Briggs In-
stitute Critical Appraisal tools were chosen for their comprehensive
scope, but were considered inappropriate for the critical appraisal of
randomized studies. Studies without a matching critical appraisal
checklist are discussed in the results and discussion sections.
2.5. Data analysis
The regular (i.e. current) regimen and alternative regimens are
deﬁned as discontinuation seven days and discontinuation between one
to seven days after return from a malaria-endemic area, respectively. To
avoid eliminating relevant studies, we used non-speciﬁc inclusion cri-
teria and limited exclusion criteria. The available data were too het-
erogenous to support a meta-analysis.
2.6. Deviations from PRISMA guidelines
The systematic review deviates from the PRISMA guidelines at
several aspects. See Appendix 3 for the PRISMA 2009 checklist. The
deviations included the absence of a risk of bias assessment due to the
heterogeneity in study selection, and therefore the impossibility of
comparing the results.
3. Results
The initial search identiﬁed 1,482 studies of which 40 studies were
included after thorough analysis based on title and abstract. The PRISMA
ﬂow diagram is shown in Fig. 1. The 40 studies were screened on full
text, after which 32 studies were found eligible. We also identiﬁed three
additional studies by additional reading/citation that had initially been
excluded based on title and abstract. This resulted in a total number of 32
eligible studies. Few studies evaluated a parasitaemia outcome. The
reasons for exclusion of the eight studies were the limited number of
patients in ﬁve studies, focus on malaria cases alone in one of the case
series, using data of already included studies in a comparative study, and
a focus on evaluation of treatment in another study. The eligible studies
for the regular and alternative regimen will be discussed separately.
3.1. Overview of the studies in support of the current post-travel regimen
3.1.1. Study designs
The total number of eligible studies that provide data about the
eﬀectiveness of the current regimen for AP prophylaxis is 21 (see
Fig. 1. Study selection (PRISMA ﬂow diagram).
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Table 1 for an overview of the eligible studies). Of the 21 studies, there
are 12 randomized studies and nine observational studies. Seven studies
used a randomized, double-blind, placebo-controlled design
[10,24–29]. Three studies used a randomized, double-blind design
without a placebo arm [17,18,30]. One randomized study challenged
volunteers with P. falciparum-infected mosquitoes [10]. Another ran-
domized study was based on direct venous inoculation of P. falciparum
sporozoites with an additional parallel open-label control cohort of AP
[31]. One study was a randomized open-label study [32]. The ob-
servational study designs included three retrospective studies
[2,33,34], two prospective observational studies [35,36], one eligible
open-label trial [37], and one open case-control study [38]. Two studies
were considered cross-sectional studies [39,40].
3.1.2. Participants' characteristics
The demographic characteristics varied, but the studies mostly in-
cluded adults. The demographic characteristics of the patients in the
diﬀerent treatment arms in each of the randomized studies were si-
milar. Three studies were performed solely in paediatric participants
[26,29,32]. Major similarities in exclusion criteria for the randomized
studies were childbearing potential or pregnancy, concomitant use of
drugs with antimalarial potential, previous malarial infection, recent
travel to a malaria endemic area, severe adverse events (e.g. hy-
persensitivity), and co-morbidities such as HIV/AIDS, other immune-
deﬁciencies or glucose-6-phosphate dehydrogenase (G6PD) deﬁciency.
Clinical, physical, or laboratory abnormalities were also considered for
exclusion. The exclusion criteria for the open label trial reported by van
der Berg and colleagues were similar to those for the randomized stu-
dies described above [37]. Van Genderen and colleagues excluded
participants aged less than 18 years old [36].
Four of the randomized studies were performed in individuals living
in a malaria-endemic area [26–29]. In contrast, eight studies were
performed in non-immune participants [10,17,18,24,25,30–32]. Seven
of the observational studies included travellers [2,33,36–40].
3.1.3. Types of interventions
The randomized studies compared AP to placebo or several anti-
malarial drugs. Seven of the randomized studies compared AP to pla-
cebo [10,24–29], two studies compared AP to chloroquine/proguanil
[18,32], one study compared AP to meﬂoquine [30], and one four-arm
parallel study compared AP, meﬂoquine, doxycycline and chloroquine/
proguanil to each other [17]. Also, an AP group served as an additional
open-label control group in one of the randomized studies [31].
Of the observational studies three studied AP alone [35–37], one
study compared AP to meﬂoquine and chloroquine/proguanil [38], two
studies compared AP to meﬂoquine [34,39], and one study compared
AP to multiple antimalarial regimens [40]. One study compared the
prescribing patterns for several antimalarial drugs [2], while another
study evaluated the eﬀectiveness of diﬀerent antimalarial regimens
based on prescribing and surveillance data [33]. Daily dosing of 250/
100 mg AP was assumed when no information about dosage was stated.
3.1.4. Types of outcome measurement
Parasitaemia was the primary outcome in eight of the randomized
studies [10,24–29,31], whereas four of the randomized studies used
adverse events as primary outcome [17,18,30,32]. In the latter group,
eﬃcacy of malaria chemoprophylaxis was a secondary outcome in two
studies [18,30]. Three of the randomized studies were not powered to
determine the eﬃcacy for malaria prevention or to compare the dif-
ference in eﬃcacy rates between the treatment groups [17,18,32].
Parasitaemia alone [35,40] and parasitaemia and safety [37] were
the primary outcomes in two and one study each, respectively. Ques-
tionnaires were used in four of the observational studies, in which
presence of malaria infection [38], adverse events [36,39], and eﬀec-
tiveness and adverse events were the primary outcomes [34]. One of
the retrospective studies extracted data from the UK based Clinical
Practice Research Datalink (CPRD) [2] while another used surveillance
data from a Health Protection Agency website and prescribing data
obtained from the Cegedim Strategic data UK [33], both providing ef-
fectiveness estimates of antimalarial regimens.
3.1.5. Methodological quality
Ratings of the methodological quality of the studies are shown in
Table 1. The randomized studies were of excellent methodological
quality. Randomization was described by all studies, as were blinding
methods. Ten studies employed a double-blind design
[10,17,18,24–30]. A group taking AP served as an additional open-label
cohort in one of the randomized studies [31]. During completion of
critical appraisal checklists, two additional points were provided for the
non-applicable items during the critical appraisal of the randomized
open-label study of Camus and colleagues. Confounding factors were
avoided by excluding participants with a history of malaria, living in a
malaria-endemic area, and concurrent use of drugs with antiplasmodial
activity. Five of the randomized studies above used a curative treatment
phase before randomization to eliminate pre-existing malarial parasites
[25–29]. Five studies analysed the results according to a per-protocol
analysis (PP); no crossing-over was described between the treatment
arms [17,26–29]. Five studies analysed the results according to an in-
tention-to-treat analysis (ITT) [10,18,25,30,32]. Two studies provided
both a PP and ITT analysis [24,31]. The use of a PP analysis leads to a
possible overestimation of the eﬃcacy [41].
Six observational studies were rated by using the checklist for cross-
sectional studies due to the use of questionnaires or use of data on
prescribing patterns from a clinical database [2,33,34,36,39,40]. The
cohort study was rated according to the cohort study checklist [35]. The
case-control study [38] and open-label trial [37] were rated by using
the checklist for case-control studies and quasi-experimental studies,
respectively. All the rated observational studies showed medium-to-
high quality. Most studies did not identify or deal with confounding
factors, with the exception of one of the retrospective studies, which
identiﬁed and corrected for confounding factors in the analysis [33].
The resulting eﬀectiveness might still have been an overestimation
since only returning travellers were considered for analysis. Most stu-
dies rated by means of the cross-sectional checklist did not measure the
exposure in a reliable and valid way; because there was no direct ob-
servation to ensure the drugs were taken appropriately [33,34,36,39].
For example, the study reported by van Genderen and colleagues lacked
supervision of drug intake and lacked conﬁrmation of the self-reported
malaria cases, and therefore induced potential recall bias and possible
underestimation of the eﬃcacy [36]. The case-control study also lacked
observation of drug intake [38]. In the study of Kato and colleagues
there was an absence of conﬁrmation of the self-reported malaria cases
[39]. The open-label trial lacked a control group and a treatment phase
to eliminate any pre-existing parasites [37]. The prospective cohort
study cleared subjects from any pre-existing parasites using a treatment
phase before administration of AP [35].
3.1.6. Results presented
Nine randomized studies provided results by calculating the eﬃcacy
of AP [10,18,24–30]. The remaining two randomized studies were not
powered to determine the eﬃcacy of the antimalarial prophylaxis, but
no cases of malaria were identiﬁed [17,32]. The randomized study with
the open-label control cohort of AP measured the level of parasitaemia
in subjects receiving AP [31].
The study reported by van der Berg and colleagues provided success
rates [37]. The case-control study calculated the eﬃcacy by de-
termining the number of malaria cases per prescription [38]. Reported
cases of malaria were used in order to estimate an overall protective
eﬃcacy in the prospective observational study [36]. Four studies pre-
sented the number of malaria cases [34,35,39,40]. One of the retro-
spective studies presented the estimated number of malaria cases per
100,000 prescriptions [33]. One of the descriptive retrospective studies
J. Savelkoel et al. Travel Medicine and Infectious Disease 21 (2018) 3–20
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presented the results by determining the incident rate of malaria per
person-years [2]. The descriptive drug utilization study done by Bloe-
chliger and colleagues estimated the incident rate of malaria in an ex-
ploratory analysis. However, methodological shortcomings (e.g. in-
adequate reporting on malaria cases) and lack of information about
exposure were acknowledged and rendered an interpretation of the
results impossible.
3.2. Overview of the studies in support of a short post-travel regimen
3.2.1. Study designs
The total number of eligible studies in support of the alternative
regimen for AP prophylaxis was 11, including two randomized studies,
three observational studies, and six pharmacological studies (see Tables
2 and 3 for an overview of the eligible studies). The non-clinical ex-
perimental studies were considered as circumstantial evidence
(Table 3). Two studies were randomized, placebo-controlled, double-
blind trials [11,42]. The eligible observational study designs were one
quasi-experimental study [43], one retrospective cohort study [20], and
one observational open-label study [44]. Three short reports were in-
cluded [12,45,46]. Finally, three non-clinical experimental studies (i.e.
serological studies) were included [47–49].
3.2.2. Participants' characteristics
Both children and adults were represented. The demographic
characteristics of the included participants were similar. The two ran-
domized studies with sporozoite challenge excluded participants who
concomitantly used drugs with antiplasmodial activity or when the
participants had any history of malaria, travelled to a malaria-endemic
region in the past year or lived in a malaria-endemic area [11,42]. The
randomized studies also excluded participants with clinical, physical or
laboratory abnormalities, those with an underlying blood disorder, or
those with childbearing potential or pregnancy. The retrospective co-
hort study by Leshem and colleagues included travellers but excluded
persons visiting friends and relatives (VFR) [20].
The participants in the randomized studies and observational open-
label study were non-immune to malaria [11,42,44]. Lachish and col-
leagues included long-term expatriates deﬁned as travelling to work for
more than six months in West Africa [43]. The subjects in the short
reports were semi-immune to malaria [12,45,46]. Two serological
studies used P. berghei in the transmission model whilst the other ser-
ological study used P. falciparum [47–49]. No previous malaria infec-
tion has been described in the serological studies of Butcher and col-
leagues [47,49]. The subjects of Enosse and colleagues were from a
malaria-endemic area [48].
3.2.3. Types of interventions
The two randomized studies with sporozoite challenge studied dif-
ferent dosages of AP. Both studies were placebo controlled [11,42]. The
observational study with quasi-experimental set-up compared twice-
weekly dosing of AP to meﬂoquine once weekly, and a group refusing to
take any chemoprophylaxis at all [43]. The retrospective cohort study
studied the discontinuation of AP prophylaxis one day after return from
a malaria-endemic area [20]. The open-label study studied AP alone,
comparing those who complied with those who did not [44]. Two short
reports provided information about the time until ﬁrst parasitaemia
after treatment with AP [45,46]. The short report of Edstein and col-
leagues studied the half-life of atovaquone after treatment with AP for
three days [12]. Three experimental, non-clinical (serological) studies
studied the inhibition of malarial transmission after treatment with AP
[47–49]. Dosing of 250/100 mg AP was assumed when no information
about dosage was stated.
3.2.4. Types of outcome measurement
Microscopic parasitaemia was the primary outcome for four studies
[11,42,45,46], of which two were randomized studies, and two short
reports. Polymerase chain reaction (PCR) was also performed in the
randomized studies with sporozoite challenge, but not in real time.
Lachish and colleagues used incidence rates as outcome, but the method
of outcome measurement was not clearly stated apart from observation
of adherence by paramedics or self-reporting [43]. Leshem and col-
leagues used active surveillance by retrospective telephone survey one
to six months after travellers' return [20]. Petersen and colleagues de-
termined the long-term safety and compliance as primary outcome
[44]. Edstein and colleagues measured the mean plasma concentrations
of atovaquone by using high-pressure liquid chromatography (HLPC) to
determine the half-life [12]. The experimental non-clinical (i.e. ser-
ological) studies determined the parasite count after dissection of the
mosquitoes [47–49].
3.2.5. Methodological quality
Ratings of the methodological quality of the studies are shown in
Table 2. The randomized studies showed excellent methodological
quality. Randomization was described by both studies, as well as
blinding methods. Both studies were conducted using a double-blind
design, with identical capsules containing either AP or placebo. Con-
founding factors were avoided by excluding participants with a history
of malaria, those living in a malaria-endemic area, and concurrent use
of drugs with antiplasmodial activity. The study of Deye and colleagues
analysed the results according to protocol, but no crossing-over was
described between the treatment arms [42]. The study of Shapiro and
colleagues hinged on an intention-to-treat analysis [11].
The retrospective cohort study of Leshem and colleagues had several
methodological shortcomings: inadequate power, possible recall bias,
travel to a region with limited risk of exposure, no evidence of malaria
exposure and insuﬃcient data ensuring that the drugs were taken ap-
propriately [20]. Outcomes were not measured in a valid way due to
the absence of using a validated survey tool. No confounding factors
were stated, but excluding VFRs can be seen as an attempt to eliminate
confounding by semi-immunity. No information was provided on
whether the participants were malaria parasite-free at study start.
The quasi-experimental study of Lachish and colleagues was of in-
termediate quality [43] as the major target travel region posed a limited
risk of exposure. No clear comparison of the demographic character-
istics of the three diﬀerent study groups was possible. However, the
authors did adjust for sex and location to compare the treatment
groups, which is an indication of similarity between the participants.
Secondly, the living conditions were similar. Unfortunately, no curative
treatment was initiated to eliminate patent parasitaemia. No clear in-
formation was provided about outcome measurement. Again, this study
was not powered to provide the eﬃcacy of an alternative regimen of AP
prophylaxis.
The observational open-label study of Petersen and colleagues was
of intermediate quality, but lacked appropriate observation of drug
intake [44]. No confounding factors were identiﬁed or dealt with;
however, it needs to be noted that the study's primary focus was ad-
verse events rather than eﬃcacy of the AP regimen.
The short reports and the three experimental non-clinical studies
were not rated by means of a checklist [12,45–49].
3.2.6. Results
The randomized studies provided data on the eﬀectiveness of the
prophylactic regimen [11,42]. The quasi-experimental study of Lachish
and colleagues determined the incidence of malaria infection in cases of
malaria per person-months [43]. Both the retrospective cohort and the
observational open-label studies yielded no cases of malaria [20,44].
Edstein and colleagues determined the half-life of atovaquone, whereas
the other two short reports determined the time until ﬁrst parasitaemia
after AP treatment [12,45,46]. The three experimental (i.e. serological)
non-clinical studies focused on the prolonged inhibition of transmission
and asexual parasite development [47–49].
J. Savelkoel et al. Travel Medicine and Infectious Disease 21 (2018) 3–20
10
Ta
bl
e
2
C
ha
ra
ct
er
is
ti
cs
of
th
e
st
ud
ie
s
in
su
pp
or
t
of
an
ab
ri
dg
ed
po
st
-t
ra
ve
l
re
gi
m
en
.
A
ut
ho
r,
ye
ar
of
pu
bl
ic
at
io
n,
co
un
tr
y
St
ud
y
de
si
gn
N
um
be
r
of
pa
rt
ic
ip
an
ts
St
ud
ie
d
an
ti
m
al
ar
ia
l
ag
en
t
M
ea
su
re
of
ou
tc
om
e
an
d
re
su
lt
s
C
ri
ti
ca
l
ap
pr
ai
sa
l
sc
or
e
D
ey
e
et
al
.,
20
12
[4
2]
U
ni
te
d
St
at
es
,W
al
te
r
R
ee
d
A
rm
y
In
st
it
ut
e
of
R
es
ea
rc
h
R
an
do
m
iz
ed
,
pl
ac
eb
o-
co
nt
ro
lle
d,
do
ub
le
-b
lin
d
tr
ia
l
in
cl
ud
in
g
ch
al
le
ng
e
by
P.
fa
lc
ip
ar
um
-i
nf
ec
te
d
m
os
qu
it
oe
s
on
da
y
0.
Th
e
co
nt
ro
l
co
ho
rt
en
ro
lle
d
as
an
op
en
-la
be
l
st
ud
y.
Fo
llo
w
-u
p
du
ra
ti
on
of
90
da
ys
.
36
pa
rt
ic
ip
an
ts
,o
fw
hi
ch
35
in
cl
ud
ed
in
th
e
IT
T
an
al
ys
is
:
23
m
en
an
d
12
no
n-
pr
eg
na
nt
/n
on
-la
ct
at
in
g
w
om
en
,
w
it
h
a
m
ea
n
ag
e
31
.2
ye
ar
s
(S
D
8.
6,
ra
ng
e
20
–5
0)
.3
3
su
bj
ec
ts
w
er
e
in
cl
ud
ed
in
th
e
A
TP
an
al
ys
is
.
A
P
25
0/
10
0
m
g
d-
1
gr
ou
p:
5
m
en
,1
w
om
an
,m
ea
n
ag
e
of
35
.7
ye
ar
s
(S
D
9.
4,
ra
ng
e
22
–4
8)
A
P
25
0/
10
0
m
g
d+
4
gr
ou
p:
1
m
en
,4
w
om
en
,m
ea
n
ag
e
of
31
.2
ye
ar
s
(S
D
8.
2,
ra
ng
e
24
–4
4)
30
su
bj
ec
ts
ra
nd
om
iz
ed
:
6
su
bj
ec
ts
re
ce
iv
ed
A
P
25
0/
10
0
m
g
on
d-
1,
6
re
ce
iv
ed
A
P
25
0/
10
0
m
g
on
d+
4,
6
re
ce
iv
ed
A
P
25
0/
10
0
m
g
on
d-
7,
6
re
ce
iv
ed
A
P
50
0/
20
0
m
g
on
d-
7,
an
d
6
re
ce
iv
ed
A
P
1,
00
0/
40
0
m
g
on
d-
7.
Th
e
co
nt
ro
l
gr
ou
p
co
m
pr
is
ed
of
6
in
fe
ct
iv
it
y
co
nt
ro
ls
.
Bl
oo
d
sm
ea
r
on
da
ys
6–
20
an
d
da
y
23
or
w
he
n
m
al
ar
ia
in
fe
ct
io
n
w
as
ex
pe
ct
ed
.C
lo
se
ob
se
rv
at
io
n
fr
om
da
y
9–
20
.A
TP
an
al
ys
is
:6
/6
su
bj
ec
ts
re
ce
iv
in
g
A
P
25
0/
10
0
m
g
on
d-
1
an
d
4/
4
re
ce
iv
in
g
A
P
25
0/
10
0
m
g
on
d
+
4
w
er
e
10
0%
pr
ot
ec
te
d.
Si
ng
le
-
do
se
A
P
pr
ov
es
to
be
10
0%
eﬀ
ec
ti
ve
pr
op
hy
la
xi
s
ag
ai
ns
t
P.
fa
lc
ip
ar
um
at
w
ee
kl
y
do
si
ng
or
w
he
n
us
ed
as
po
st
-
ex
po
su
re
pr
op
hy
la
xi
s
4
da
ys
af
te
r
ch
al
le
ng
e.
<
5/
5
fo
llo
w
in
g
Ja
da
d
ch
ec
kl
is
t
Sh
ap
ir
o
et
al
.,
19
99
[1
1]
N
at
io
na
l
In
st
it
ut
es
of
H
ea
lt
h
(B
et
he
sd
a,
M
D
)
–
sp
on
so
re
d
ou
tp
at
ie
nt
G
en
er
al
C
lin
ic
al
R
es
ea
rc
h
C
en
te
r
of
th
e
Jo
hn
s
H
op
ki
ns
H
os
pi
ta
l,
U
ni
te
d
St
at
es
R
an
do
m
iz
ed
,
do
ub
le
-b
lin
d,
pl
ac
eb
o-
co
nt
ro
lle
d
st
ud
y
in
cl
ud
in
g
ch
al
le
ng
e
by
P.
fa
lc
ip
ar
um
-i
nf
ec
te
d
m
os
qu
it
oe
s.
Fo
llo
w
-u
p
of
12
w
ee
ks
af
te
r
ch
al
le
ng
e.
D
ay
of
ch
al
le
ng
e
is
de
si
gn
at
ed
st
ud
y
da
y
0.
16
su
bj
ec
ts
(6
hi
gh
do
se
,6
lo
w
do
se
,
an
d
4
pl
ac
eb
o)
w
it
h
an
av
er
ag
e
ag
e
of
30
.1
ye
ar
s
(r
an
ge
22
–4
4)
,o
fw
hi
ch
1
w
om
an
.
Se
ve
n
da
ily
do
se
s
of
75
0
m
g
at
ov
aq
uo
ne
vs
.s
in
gl
e
do
se
of
25
0
m
g
at
ov
aq
uo
ne
pl
us
pl
ac
eb
o
ta
bl
et
s
vs
.
pl
ac
eb
o.
A
ll
do
se
d
pr
io
r
to
sp
or
oz
oi
te
ch
al
le
ng
e.
Bl
oo
d
sm
ea
r
an
d
as
se
ss
m
en
t
vi
si
ts
da
ily
(d
ay
s
5–
21
),
ev
er
y
ot
he
r
da
y
(d
ay
s
22
–3
5)
,a
nd
th
en
w
ee
kl
y
un
ti
l
12
w
ee
ks
af
te
r
ch
al
le
ng
e.
PC
R
an
d
cu
lt
ur
e
w
er
e
pe
rf
or
m
ed
to
co
nﬁ
rm
pa
ra
si
ta
em
ia
.2
50
m
g
of
at
ov
aq
uo
ne
pr
ot
ec
te
d
6/
6
su
bj
ec
ts
,
an
d
ei
th
er
of
th
e
at
ov
aq
uo
ne
re
gi
m
en
s
pr
ov
id
es
eﬀ
ec
ti
ve
(1
00
%
)
pr
op
hy
la
xi
s
co
m
pa
re
d
to
pl
ac
eb
o
(P
=
.0
05
,9
5%
C
I
of
pr
ot
ec
ti
on
=
61
–1
00
%
).
4/
5
fo
llo
w
in
g
Ja
da
d
ch
ec
kl
is
t
La
ch
is
h
et
al
.,
20
16
[4
3]
In
fe
ct
io
us
di
se
as
es
cl
in
ic
Is
ra
el
,
lo
ng
-t
er
m
ex
pa
tr
ia
te
s
in
A
ng
ol
a
an
d
Eq
ua
to
ri
al
G
ui
ne
a
O
bs
er
va
ti
on
al
su
rv
ei
lla
nc
e
st
ud
y
us
in
g
a
qu
as
i-
ex
pe
ri
m
en
ta
l
se
t-
up
w
it
h
1,
36
8
pe
rs
on
-m
on
th
s
of
fo
llo
w
-
up
12
2
lo
ng
-t
er
m
ex
pa
tr
ia
te
s
tr
av
el
lin
g
to
w
or
k
in
W
es
t
A
fr
ic
a,
of
w
hi
ch
33
su
bj
ec
ts
to
ok
A
P
tw
ic
e
w
ee
kl
y.
14
ex
pa
tr
ia
te
s
(a
ll
m
al
e,
m
ed
ia
n
ag
e
of
24
ye
ar
s)
sw
it
ch
ed
fr
om
no
-
pr
op
hy
la
xi
s
to
A
P
in
th
e
A
ng
ol
a
ju
ng
le
s
fo
r
10
m
on
th
s.
10
8
su
bj
ec
ts
(m
:f
=
1:
1;
ag
e
ra
ng
e
1.
5–
71
;2
8
of
10
7
w
er
e
≤
12
ol
d)
liv
ed
fo
r
di
ﬀ
er
en
t
pe
ri
od
s
(m
ed
ia
n
st
ay
=
19
.4
5
m
on
th
s)
in
Eq
ua
to
ri
al
G
ui
ne
a.
A
P
tw
ic
e
w
ee
kl
y
vs
.m
eﬂ
oq
ui
ne
vs
.
gr
ou
p
re
fu
si
ng
to
ta
ke
pr
op
hy
la
xi
s.
A
dh
er
en
ce
w
as
ob
se
rv
ed
by
pa
ra
m
ed
ic
s
an
d
se
lf
-r
ep
or
ti
ng
.
M
al
ar
ia
in
ci
de
nc
e
w
as
lo
w
er
in
A
P
gr
ou
p
(0
/3
91
pe
rs
on
-m
on
th
s,
95
%
C
I
=
1.
4–
∞
,P
=
.0
1)
th
an
in
no
-
pr
op
hy
la
xi
s
gr
ou
p
(1
1.
7/
1,
00
0
pe
rs
on
-m
on
th
s)
.
A
ft
er
ad
ju
st
m
en
t,
tr
ea
tm
en
t
w
as
as
so
ci
at
ed
w
it
h
∼
20
ti
m
es
de
cr
ea
se
d
od
ds
fo
r
m
al
ar
ia
co
m
pa
re
d
w
it
h
no
pr
op
hy
la
xi
s:
O
R
=
0.
05
(9
5%
C
I
=
0.
00
6–
0.
42
;P
=
.0
06
).
5/
9
fo
llo
w
in
g
ch
ec
kl
is
t
fo
r
qu
as
i-
ex
pe
ri
m
en
ta
l
st
ud
ie
s
Le
sh
em
et
al
.,
20
14
[2
0]
A
ct
iv
e
su
rv
ei
lla
nc
e
in
tr
av
el
cl
in
ic
Is
ra
el
R
et
ro
sp
ec
ti
ve
co
ho
rt
st
ud
y
be
tw
ee
n
20
10
an
d
20
11
48
5
tr
av
el
le
rs
to
su
b-
Sa
ha
ra
n
A
fr
ic
a
of
w
hi
ch
42
1
su
bj
ec
ts
us
ed
a
sh
or
t-
co
ur
se
of
A
P
pr
op
hy
la
xi
s.
21
9
(5
2%
)
m
al
e,
m
ea
n
ag
e
of
38
.1
±
20
.3
ye
ar
s
(m
ed
ia
n
ag
e
43
ye
ar
s,
ra
ng
e
4–
76
),
an
d
m
ea
n
tr
av
el
du
ra
ti
on
of
10
.1
–
7.
8
da
ys
(m
ed
ia
n
10
da
ys
,r
an
ge
2–
77
).
42
1/
48
5
(8
7%
)
di
sc
on
ti
nu
ed
A
P
1
da
y
af
te
r
le
av
in
g
en
de
m
ic
ar
ea
(c
um
ul
at
iv
e
ex
po
su
re
of
4,
33
7
da
ys
)
co
m
pa
re
d
to
9
(2
%
)
tr
av
el
le
rs
(c
um
ul
at
iv
e
pe
ri
od
of
95
tr
av
el
da
ys
)
co
nt
in
ue
d
ta
ki
ng
A
P
fo
r
2–
7
da
ys
af
te
r
le
av
in
g
en
de
m
ic
ar
ea
;a
nd
55
(1
1%
)
tr
av
el
le
rs
(c
um
ul
at
iv
e
pe
ri
od
of
54
7
tr
av
el
da
ys
)
di
d
no
t
ta
ke
A
P
pr
op
hy
la
xi
s
at
al
lo
r
di
sc
on
ti
nu
ed
A
P
pr
io
r
to
le
av
in
g
th
e
en
de
m
ic
co
un
tr
y.
A
ct
iv
e
su
rv
ei
lla
nc
e
du
ri
ng
20
10
–2
01
1
by
re
tr
os
pe
ct
iv
e
te
le
ph
on
e
su
rv
ey
1–
6
m
on
th
s
af
te
r
tr
av
el
le
rs
'r
et
ur
n.
N
on
e
of
th
e
48
5
tr
av
el
le
rs
re
po
rt
ed
m
al
ar
ia
in
fe
ct
io
n.
2/
7
ap
pl
ic
ab
le
it
em
s,
(2
/1
1
of
to
ta
l
sc
or
e)
fo
llo
w
in
g
ch
ec
kl
is
t
fo
r
co
ho
rt
st
ud
ie
s
Pe
te
rs
en
et
al
.,
20
03
[4
4]
G
as
tr
oi
nt
es
ti
na
l
an
d
Pa
ra
si
ti
c
In
fe
ct
io
ns
cl
in
ic
O
bs
er
va
ti
on
al
op
en
-la
be
l
st
ud
y
w
it
h
no
po
ss
ib
ili
ty
of
fo
llo
w
-u
p
du
e
to
th
e
an
on
ym
ou
s
qu
es
ti
on
na
ir
es
.
18
4
(6
1%
)
no
n-
im
m
un
e
so
ld
ie
rs
ﬁ
lle
d
in
th
e
qu
es
ti
on
na
ir
es
.
17
6
(9
6%
)
w
er
e
m
al
e
w
it
h
a
m
ea
n
ag
e
of
30
ye
ar
s.
A
P
pr
op
hy
la
xi
s
w
it
ho
ut
co
nt
ro
l
gr
ou
p.
A
na
ly
si
s
th
er
ef
or
e
co
m
pa
re
d
se
lf
-r
ep
or
te
d
sy
m
pt
om
s
in
so
ld
ie
rs
w
ho
w
er
e
co
m
pl
ia
nt
(i
.e
.t
ak
in
g
at
le
as
t3
of
ev
er
y
4
ta
bl
et
s
du
ri
ng
th
e
6-
m
on
th
pe
ri
od
)
w
it
h
so
ld
ie
rs
w
ho
re
po
rt
ed
ta
ki
ng
fe
w
er
.
Po
st
-t
ra
ve
l
qu
es
ti
on
na
ir
es
.
44
su
bj
ec
ts
w
er
e
to
ta
l
co
m
pl
ia
nt
,
37
to
ok
3/
4
pi
lls
,
29
to
ok
2/
4
pi
lls
,a
nd
63
to
ok
1/
4
pi
lls
or
fe
w
er
.1
1
to
ok
no
ne
at
al
l.
N
o
ca
se
s
of
fa
lc
ip
ar
um
m
al
ar
ia
w
er
e
re
co
rd
ed
.
5/
8
fo
llo
w
in
g
ch
ec
kl
is
t
fo
r
cr
os
s-
se
ct
io
na
l
st
ud
ie
s
(c
on
tin
ue
d
on
ne
xt
pa
ge
)
J. Savelkoel et al. Travel Medicine and Infectious Disease 21 (2018) 3–20
11
4. Discussion
This is the ﬁrst systematic review to provide a comprehensive
overview of evidence on the eﬃcacy of both the recommended and
alternative regimens of AP prophylaxis. The literature search yielded
some limited clinical and non-clinical evidence suggesting that a short
post-travel regimen of AP is potentially eﬀective, but requires further
investigation. The total sample size and quality of those studies com-
prise a relatively small percentage of the total sample size and quality of
the studies with evidence in support of the current post-travel regimen;
information which must be taken into account when weighing the
evidence for a curtailed regimen.
4.1. Studies in support of the current post-travel regimen
The randomized studies performed with a seven day post-travel
regimen show high eﬃcacy as determined by the systematic review of
Nakato and colleagues [50]. This previously conducted systematic re-
view performed a meta-analysis of six of the twelve randomized studies
included in our systematic review. The meta-analysis of the six studies
found an eﬃcacy of 95.8% (95% CI = 91.5–97.9) [24–29]. Five of the
other randomized studies included in this systematic review, but not
part of the meta-analysis of Nakato and colleagues, described no cases
of falciparum malaria in AP recipients [10,17,30–32]. The last rando-
mized study provided an estimated minimum eﬃcacy for prevention of
P. falciparum of 100% (95% CI = 59–100) [18]. The single study of
Berman and colleagues led to the clinical studies, as described above,
and ultimately resulted in the implementation of the currently re-
commended post-travel regimen of seven days [10].
An interesting ﬁnding is that three of the randomized studies de-
scribed that a percentage of the participants took less than 80% of the
recommended doses in the post-travel period, but none of those parti-
cipants developed malaria (3%, 7%, 12%) [18,30,32]. No information
was provided about the total number of missed pills, or days on which
pills were not taken. However, it raises the question whether it is ne-
cessary to fully adhere to the current post-travel regimen.
The descriptive retrospective drug utilization study was selected to
demonstrate the eﬀectiveness of AP when prescribed as prophylactic
agent, namely 13 cases per 100,000 person years [2]. Another retro-
spective study determined the number of falciparum malaria cases to be
1.3 per 100,000 prescriptions of AP [33]. Both are proof that AP is a
highly eﬀective agent for the prevention of clinical malaria episodes, as
is the study in which no cases of malaria were described in the col-
lectors who were performing human landing catches while receiving AP
[35]. The latter study highlights the eﬃcacy of AP even in a high-risk
setting. The open case-control study, in which 45 travellers used AP,
estimated the number of falciparum malaria cases per prescription in
fully compliant users to be 1 per 1,943 [38]. Finally, the observational
study with 57 person-years of follow-up [36] and the open-label trial
with a ten-week duration [37] determined the eﬃcacy and prophylactic
success of AP prophylaxis against falciparum malaria both to be 97%;
no cases of malaria were described in the latter study. The success rate
consisted of people who did not develop parasitaemia and did not
withdraw due to a treatment-related adverse event. The prophylactic
eﬃcacy estimated in the study by van Genderen and colleagues may
even be an underestimation since they were not able to verify the di-
agnosis of the self-reported malaria cases [36].
4.2. Studies in support of a short post-travel regimen
The randomized controlled clinical trials of Deye and colleagues
with sporozoite challenge with very few subject numbers supports the
hypothesis of weekly dosing of AP and stated that once weekly and
post-exposure prophylaxis four days after challenge was 100% eﬀective
[42]. None of the participants developed malaria. The post-exposure
dose four days after challenge is in line with the observational study ofTa
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Lachish and colleagues with a twice-weekly dosing schedule in which
no cases of malaria were recorded [43]. It needs to be stressed that the
methodology for these studies was weak and exposure varied. The re-
sults are in line with the observational open-label study of Petersen and
colleagues where no cases of falciparum malaria were recorded in
participants who took one out of four pills (i.e. consistent with twice-
weekly prophylaxis) [44].
In line with the information provided by Deye and colleagues, the
randomized sporozoite challenge study of Shapiro and colleagues, again
with very limited subject numbers, described no malaria cases when
dosed one day before malaria challenge with a broad conﬁdence in-
terval (95% CI = 61–100%) [11]. This raises the hypothesis of an ab-
breviated post-travel course. The observational study of Leshem and
colleagues found that none of participants who discontinued AP one
day after return from a malaria-endemic area developed malaria [20].
Finally, several studies related to pharmacological aspects of AP
have been included. The short report of Edstein and colleagues de-
termined the half-life of atovaquone to be 5.9 days by HLPC in contrast
to the currently accepted half-life of two to three days in adults [12].
The other two short reports both determined the time until ﬁrst para-
sitaemia after malaria treatment with AP to be 32 days [45,46], which
cannot be explained by the currently accepted elimination half-life.
These results support the data on the half-life properties of atovaquone
provided by Edstein and colleagues, and suggest that a regimen of AP
taken less frequently than daily may be eﬀective. This prolonged in-
hibitory activity was further illustrated by the complete inhibition of
schizont formation until day 35 post-treatment [12]. However, a point
of critique on the justiﬁcation of a short course of AP based on this half-
life is the questionable eﬃcacy when subjects are in the end exposed to
atovaquone alone due to the short half-life of proguanil. Additionally,
regimens spreading out the AP doses could leave the travellers with
primarily atovaquone and thus also potentially inducing atovaquone
resistance. Taking these points into consideration, atovaquone-only
exposure due to an abbreviated course of AP might ultimately result in
AP resistance.
Non-clinical experimental (i.e. serological) studies were considered
as circumstantial evidence to support the theory of a half-life of 5.9
days, because the inhibition of asexual blood stages (responsible for
clinical malaria episodes) was less pronounced than the inhibition of
sexual blood stages (responsible for transmission), suggesting a diﬀer-
ence in sensitivity to AP. The results on inhibition on the diﬀerent
stages of the asexual and sexual blood stage development shown in
Table 3 were also extracted to demonstrate the diﬀerences in inhibitory
potential depending on the various stages.
The diﬀerences in the inhibition of sexual stage development of
malaria are beyond the scope of this systematic review. However the
prolonged inhibitory potential may suggest that concentrations of AP
have inhibitory potential, which cannot be explained by our current
understanding of the half-life properties.
The sera after treatment with AP completely inhibited transmission
until day 28 in P. falciparum and in the P. berghei model, respectively
[47,48]. Again, the long inhibitory activity of AP cannot be explained
by our current understanding of the half-life properties. The remaining
P. berghei study showed an inhibitory potential of transmission until day
14, in contrast to the inhibitory potential of 28 days (when considering
the gametocyte-oocyst stadium as transmission potential) [49]. How-
ever, the sensitivity diﬀers between the diﬀerent stages of the malaria
cycle, and therefore this evidence should be considered only as cir-
cumstantial. One of the studies of Butcher and colleagues showed that
atovaquone-only serum totally inhibited transmission up to, and in-
cluding, day 28; suggesting that it is the persistence of atovaquone that
is responsible for the prolonged inhibitory eﬀect [47], whilst the other
study of Butcher and colleagues totally inhibited oocyst formation be-
tween days 3 and 21 [49]. The circumstantial results illustrate that AP
is not gametocytocidal, because gametocytes quickly declined only to
rise again after days to weeks.
4.3. Key ﬁndings and failure rates
The failure rates in the studies with a focus on the seven-day post
travel regimen are higher in comparison to the studies in support of a
short post-travel regimen (see Tables 4 and 5 for key ﬁndings and
failure rates). However, the total number of subjects in studies in sup-
port of a short post-travel regimen is considerable smaller than the
respective number in support of the current post-travel regimen. Sec-
ondly, the eﬃcacy of the full course of AP is 95.8% [50] and so we
should expect a few failures in the abbreviated regimen in case we
expect a prolonged inhibitory potential of AP. Also, the observational
studies with no reported malaria cases might not reﬂect the true eﬃ-
cacy of a short post-travel regimen due to ﬂaws in their study metho-
dology [20,43]. This should be taken into account when comparing and
interpreting the regimens based on our ﬁndings. Finally, it should be
stressed that the two randomized studies in support of a short post-
travel regimen were performed under ideal conditions, that is, under
the supervised administration of the drug together with a (fatty) meal,
and, secondly, that the daily habits of the subjects were not disrupted in
a way one could expect in travellers at the end or after a prolonged
travel from endemic regions [11,42]. In the case of travellers, disrupted
daily routines with irregular meals may result in the ingestion of AP
while fasting, resulting in a decreased maximum concentration and
therefore the possibility of prophylactic failure (see 4.4).
4.4. Additional data on alternative prophylactic regimens
Caution is warranted when considering alternative prophylactic
regimens, as illustrated by the following data on use of AP for pro-
phylaxis among those with malaria from 2006 to 2014. Malaria is a
mandatorily reportable disease in the U.S. The National Malaria
Surveillance System (NMSS) collects information on malaria cases, in-
cluding type of prophylaxis taken and adherence. From 2006 to 2014,
there were 354 malaria cases that reported taking AP for malaria pro-
phylaxis. Of these, 176 had acute malaria, deﬁned as onset< 45 days
after arrival, and took AP exclusively for prophylaxis. Information on
adherence was available for 153 out of 176. While 53 out of 153 (35%)
took AP with good adherence, most (100 out of 153, 65%) missed
doses. Of these, 90 patients had additional data on missed doses.
Eighteen of the 90 patients (20%) reported stopping AP prematurely
after returning home. All of these patients travelled to Africa (West
Africa-10, East Africa-4, Central Africa-3, unspeciﬁed sub-Saharan
African country-1) with a median trip duration of 21 days (range 9–300
days). Two of these patients had severe malaria. This strong evidence
against a shortened regimen highlights the need for additional research
before short post-travel AP regimens can be recommended for use in
routine practice.
Caution against changing the current regimen is further supported
by the key issue in AP absorption, namely the need for AP intake with a
fatty meal, as not doing so may result in sub-therapeutic drug con-
centrations and ultimately a fatal outcome due to prophylactic failure.
Atovaquone has a very low aqueous solubility and to ascertain ab-
sorption, it needs to be taken with fatty food, as the ingestion with food
leads to a 5-fold increase in maximum plasma concentration, compared
to ingestion with water alone [8]. Illustrated by the following case re-
port [51], we aim to demonstrate that even full adherence to AP might
result into prophylactic failure when one does not co-administer AP
with a fatty meal. The patient took AP on an empty stomach, which
resulted in sub-therapeutic concentrations of atovaquone and proguanil
by 1,000-fold and 100-fold, respectively. The problem described above
might have contributed to some of the failures in the included studies.
The reason we present this key issue is that in the case of travellers,
altered activity patterns with irregular meals may result in the ingestion
of AP while fasting, resulting in a decreased maximum concentration,
and therefore the possibility of prophylactic failure.
Another reason for presenting this data is that the two randomized
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studies that observed AP being eﬀective after a single dose might have
been an over-estimation, because the studies were performed in con-
trolled settings with observed intake of the pills during or following a
meal [11,42]. In the absence of this meal, one might question whether
the same results with respect to eﬀectiveness would have been ob-
tained, as the maximum concentrations might have been decreased, the
latter being probably more frequently the case in travellers.
4.5. Rationale for the current antimalarial regimens
The diﬀerent regimens for prophylactic agents depend on the stages
of the malaria parasite being targeted by the active drug compounds,
and so the current prophylactic regimens are based upon the pharma-
codynamic properties of the antimalarial agents. Because AP exerts
causal prophylactic activity, it can be discontinued seven days after
return from a malaria-endemic area instead of one month in the case of
antimalarials with only suppressive eﬀects against blood stages of
malaria, such as chloroquine, meﬂoquine, and doxycycline [1]. This is
to assure the eradication of any parasites released from the liver in the
following month due to the fact that merozoites are released from the
liver after approximately 7–23 days [52].
4.6. Strengths and limitations
The methodological strengths of this systematic review include the
all-encompassing search strategy and the non-speciﬁc inclusion criteria.
The search strategy included additional terms related to pharmacoki-
netic properties of AP in order to identify articles that might have been
missed when only focusing on the terms related to prophylaxis and half-
life properties of AP. The non-speciﬁc inclusion criteria provided the
possibility to identify relevant articles without overlooking studies that
would not have met more speciﬁc criteria. Studies considered for in-
clusion either provided evidence in support of the current regimen or
the alternative regimen, which our hypothesis is based on. This gave us
the possibility to compare the evidence.
Several limitations have to be acknowledged. Regarding internal
validity; ﬁrst of all, no meta-analysis was possible in our systematic
review due to the enormous heterogeneity in eligible study designs,
outcome measurements and presentation of results. This heterogeneity
in eligible studies also led to the omission of performing a risk-of-bias
assessment, because the results could not be compared. Secondly, our
search only focused on the combination of both atovaquone and pro-
guanil, and only one article with focus on solely atovaquone has been
included by citation, but when bearing in mind that it is only atova-
quone that is responsible for the prolonged inhibitory eﬀect of AP, an
additional search with a speciﬁc focus on atovaquone should have been
part of the search strategy.
Regarding the external validity, a limitation in determining the ef-
ﬁcacy is the fact that almost all controlled studies were of small sample
size, and were therefore not powered to evaluate the prophylactic ef-
ﬁcacy. In addition, exposure regions varied in the included studies.
Because the exposure was not uniform, one might question whether the
eﬃcacy of the included studies can be compared at all. Further lim-
itations include the fact that the observational studies of Lachish and
Leshem were performed in a region with limited risk of exposure
[20,43]. The lack of a control group can be another major limitation in
observational studies. The disadvantage of the randomized challenge
studies is the limited intensity of exposure compared to the randomized
studies performed in highly endemic regions [11,42]. The eﬀects of the
short reports reﬂect both drug eﬀect and immunity, and might therefore
lead to over-estimate the results [12,45,46]. Taking the collective
limitations related to external validity into account, the results in
support of an alternative post-travel regimen may have been an over-
estimation.
4.7. Methodological approaches in determining alternative regimens for
malaria prophylaxis
In of reviewing studies regarding malaria prophylaxis in general,
and the use of AP prophylaxis in particular, we acknowledge the lim-
itations when putting alternative regimens of malaria prophylaxis to the
test. The methodological approaches of Leshem and Lachish are bold
eﬀorts to evaluate alternative, shorter prophylactic regimens; however,
the limited risk of exposure (not a methodological error due to poor
choices but dependent on the travel destinations chosen by the study
cohort; with few subjects destined for highly endemic malaria areas
such as West and Central Africa) made the results inferior to those of
randomized controlled studies in support of the current post-travel re-
gimen of AP. The pharmaceutical industry may have limited interest in
pursuing randomized controlled trials to determine the eﬃcacy of al-
ternative prophylactic regimens. Therefore, the randomized controlled
studies with P. falciparum challenge as performed by Deye and Shapiro
could be seen as a solution in dealing with those limitations. Both the
limited risk of exposure and lack of a control group would be resolved.
In our opinion, this less complex methodological study design could
replace the current gold standard of randomized controlled studies
within the travel medicine community when considering putting al-
ternative prophylactic approaches to the test. This being said, ob-
servational studies with a solid methodological approach might also
provide relevant data on alternative AP regimens when the study
methodology is solid with numerous subject numbers. A suggestion
when studying alternative regimens of AP would therefore be to pay
Table 5
Failure rates of the studies in support of a short post-travel regimen.
Author Study size Eﬃcacy Failures
Deye et al., 2012 [42] 6 subjects received AP 250/100 mg on d-1
4 subjects received AP 250/100 mg on d+4
Subjects receiving AP 250/100 mg on d-1 and AP 250/100
mg on d+4 were 100% protected.
0
Shapiro et al., 1999 [11] 6 subjects received 250 mg atovaquone 250 mg of atovaquone protected all subjects 0
Lachish et al., 2016 [43] 33 subjects received AP twice weekly Malaria incidence in AP group was 0/391 person-months 0
Leshem et al., 2014 [20] 421 subjects used a short-course of AP prophylaxis None of the subjects reported malaria infection. 0
Petersen et al., 2003 [44] 184 subjects ﬁlled in the questionnaires, of which
only the 63 subjects of the 1/4 group are included in
the total amount of subjects.
44 subjects were total compliant, 37 took 3/4 pills, 29
took 2/4 pills, and 63 took 1/4 pills or fewer. 11 took none
at all. No cases of falciparum malaria were recorded.
0
Edstein et al., 2005 [12] – – –
Polhemus et al., 2008 [45] – – –
Shanks et al., 1999 [46] – – –
Butcher et al., 2003 [47] – – –
Butcher et al., 2000 [49] – – –
Enosse et al., 2000 [48] – – –
Total subjects: 533 Total failures: 0 cases
AP, atovaquone-proguanil.
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additional attention to several shortcomings that potentially lead to
biased results or results distorted by confounding factors.
5. Conclusion
The eﬃcacy of a post-travel AP chemoprophylaxis regimen of seven
days in fully compliant volunteers has undoubtedly been established by
high quality studies. Stopping AP chemoprophylaxis on return from
travel is an attractive proposition but data demonstrating continued
protection are scarce and of limited quality.
We conclude that there is some limited direct and indirect evidence
to support the possibility of an alternative post-travel regimen for AP.
However, the total sample size of the studies to support this possibility
of which studies with focus on discontinuation one day after return
were part, comprises a small percentage of the total sample size of the
studies performed to establish the eﬃcacy of the current AP regimen.
On top of that, the methodological quality of the studies performed
with a seven day post-travel regimen outweighs the quality of the
studies with evidence for alternative regimens. Abbreviated AP regi-
mens require a closer look and additional research with numerous
subject numbers is required to fully support the hypothesis of a short
post-travel regimen of AP before a short post-travel regimen can be
implemented in current practice.
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Appendix 1. Pubmed search strategy
Number Searches
#1 Atovaquone[mesh] OR atovaquone[tiab]
#2 Proguanil[mesh] OR proguanil[tiab]
#3 Atovaquone, proguanil drug combination[Supplementary Concept] OR malarone[tiab] OR hydroxynaphthoquinone[tiab] OR Mepron
[tiab] OR Wellvone[tiab] OR atovaquone/proguanil[tiab] OR Atovaquone and Proguanil[tiab] OR Atovaquone+proguanil[tiab]
#4 Chemoprevention[Mesh:NoExp] OR prevention and control[Subheading] OR chemoprophylaxis[tiab] OR prophylaxis[tiab] OR
chemoprevention[tiab] OR pharmacokinetics[Mesh] OR pharmacokinetics[Subheading] OR pharmacokinetics[tiab] OR Half-Life
[Mesh] OR half-life*[tiab] OR halﬂife*[tiab] OR duration[tiab] OR area under curve[mesh] OR absorption[mesh] OR PK[tiab] OR PPK
[tiab] OR tmax[tiab] OR cmax[tiab] OR AUC[tiab] OR "area under the curve"[tiab] OR clearance[tiab] OR elimination[tiab] OR
"volume of distribution"[tiab] OR "drug level"[tiab] OR absorption[tiab] OR serum concentration[tiab] OR plasma concentration[tiab]
#5 #1 AND #2
#6 #3 OR #5
#7 #4 AND #6
Appendix 2. Embase search strategy
Number Searches
#1 exp atovaquone/
#2 atovaquone.ti,ab,kw,hw,tn.
#3 1 or 2
#4 exp proguanil/
#5 proguanil.ti,ab,kw,hw,tn.
#6 4 or 5
#7 3 and 6
#8 exp atovaquone plus proguanil/
#9 (malarone or hydroxynaphthoquinone or Mepron or Wellvone or "atovaquone/proguanil" or (Atovaquone adj Proguanil) or
"Atovaquone+proguanil").ti,ab,kw.
#10 8 or 9
#11 7 or 10
#12 exp chemoprophylaxis/or exp "prevention and control"/or exp pharmacokinetics/or exp half life time/or exp area under the curve/or
exp absorption/or prevention.fs. or (pharmacokinetics or half-life* or halﬂife* or duration or PK or PPK or tmax or cmax or AUC or
"area under the curve" or clearance or elimination or "volume of distribution" or "drug level" or absorption or ((serum or plasma) adj
concentration)).ti,ab,kw.
#13 11 and 12
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Appendix 3. PRISMA 2009 checklist
Section/topic # Checklist item Reported on
page #
TITLE
Title 1 Identify the report as a systematic review, meta-analysis, or both. 1
ABSTRACT
Structured summary 2 Provide a structured summary including, as applicable: background; objectives; data sources; study
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results;
limitations; conclusions and implications of key ﬁndings; systematic review registration number.
1
INTRODUCTION
Rationale 3 Describe the rationale for the review in the context of what is already known. 1–2
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants,
interventions, comparisons, outcomes, and study design (PICOS).
2
METHODS
Protocol and
registration
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if
available, provide registration information including registration number.
2
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years
considered, language, publication status) used as criteria for eligibility, giving rationale.
2
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to
identify additional studies) in the search and date last searched.
2
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it
could be repeated.
2, 15
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if
applicable, included in the meta-analysis).
2–3
Data collection
process
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and
any processes for obtaining and conﬁrming data from investigators.
2–3
Data items 11 List and deﬁne all variables for which data were sought (e.g., PICOS, funding sources) and any
assumptions and simpliﬁcations made.
2–3
Risk of bias in
individual studies
12 Describe methods used for assessing risk of bias of individual studies (including speciﬁcation of
whether this was done at the study or outcome level), and how this information is to be used in any
data synthesis.
NA
Summary measures 13 State the principal summary measures (e.g., risk ratio, diﬀerence in means). NA
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures
of consistency (e.g., I2) for each meta-analysis.
NA
Risk of bias across
studies
15 Specify any assessment of risk of bias that may aﬀect the cumulative evidence (e.g., publication bias,
selective reporting within studies).
NA
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if
done, indicating which were pre-speciﬁed.
NA
RESULTS
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for
exclusions at each
stage, ideally with a ﬂow diagram.
3
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-
up period) and provide the citations.
5–7, 9–11
Risk of bias within
studies
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item
12).
NA
Results of individual
studies
20 For all outcomes considered (beneﬁts or harms), present, for each study: (a) simple summary data for
each intervention group (b) eﬀect estimates and conﬁdence intervals, ideally with a forest plot.
NA
Synthesis of results 21 Present results of each meta-analysis done, including conﬁdence intervals and measures of
consistency.
NA
Risk of bias across
studies
22 Present results of any assessment of risk of bias across studies (see Item 15). NA
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see
Item 16]).
NA
DISCUSSION
Summary of evidence 24 Summarize the main ﬁndings including the strength of evidence for each main outcome; consider
their relevance to key groups (e.g., healthcare providers, users, and policy makers).
10–14
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Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete
retrieval of identiﬁed research, reporting bias).
14
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for
future research.
12, 14, 15
FUNDING
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of
funders for the systematic review.
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